|
PRPF4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.02349248468181E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.46944695195361E-12 |
| Normal-vs-Stage2 |
1.54748999999788E-05 |
| Normal-vs-Stage3 |
6.33220031964754E-10 |
| Normal-vs-Stage4 |
2.42289521779071E-11 |
| Stage1-vs-Stage2 |
7.555600E-01 |
| Stage1-vs-Stage3 |
3.958200E-01 |
| Stage1-vs-Stage4 |
8.169800E-02 |
| Stage2-vs-Stage3 |
4.275000E-01 |
| Stage2-vs-Stage4 |
1.398800E-01 |
| Stage3-vs-Stage4 |
3.749600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.45869999307524E-11 |
| Normal-vs-AfricanAmerican |
2.21089999999924E-05 |
| Normal-vs-Asian |
2.02629999446202E-08 |
| Caucasian-vs-AfricanAmerican |
8.872200E-01 |
| Caucasian-vs-Asian |
5.800400E-01 |
| AfricanAmerican-vs-Asian |
8.056600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.36144478707956E-12 |
| Normal-vs-Female |
7.26652071847411E-12 |
| Male-vs-Female |
2.078200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.36540001527408E-10 |
| Normal-vs-Age(41-60Yrs) |
4.02869959614804E-11 |
| Normal-vs-Age(61-80Yrs) |
4.73590056060402E-11 |
| Normal-vs-Age(81-100Yrs) |
5.724000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.391600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.784830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.665600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.163400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.825600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.635600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.799900E-02 |
| Classical-VS-Follicular |
7.620100E-04 |
| Classical-VS-Other |
2.010600E-01 |
| Classical-VS-Normal |
3.98249988542432E-10 |
| Tall-VS-Follicular |
4.827200E-01 |
| Tall-VS-Other |
6.851200E-01 |
| Tall-VS-Normal |
9.85929999863799E-08 |
| Follicular-VS-Other |
9.866200E-01 |
| Follicular-VS-Normal |
1.23160370790742E-11 |
| Other-VS-Normal |
7.204500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.9984682231875E-12 |
| Normal-vs-N1 |
5.88820103786247E-11 |
| N0-vs-N1 |
1.094240E-01 |
|
|
